Trial Testing INOpulse for PH-ILD Completes Enrollment of Second Patient Group
Bellerophon reached its enrollment goal for the second group of patients in its ongoing Phase 2/3 trial evaluating different doses of INOpulse therapy for pulmonary hypertension associated with interstitial lung disease (PH-ILD), a illness for which no treatments exist. PH-ILD patients in group (or…